Lung Cancer
Treating Metastatic Breast Cancer After Endocrine Therapy and T-DXd
During a live event, Payal D. Shah, MD, discusses the case of a woman with metastatic breast cancer and the data for third-line sacituzumab govitecan.
Read More
Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia
In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.
Listen
Ocular Events With Mirvetuximab Show No Impact on QoL in Ovarian Cancer
Juneja Explores AI’s Impact in Early Cancer Detection and Treatment
In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.
FDA Grants Approval to Durvalumab in MIBC
This approval of durvalumab marks the first and only perioperative immunotherapy regimen available in muscle-invasive bladder cancer.
FDA Expands Indication for Lutetium-177 PSMA-617 in PSMA-Positive mCRPC
The FDA approved 177Lu PSMA-617 for prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer after androgen therapy.
